Publications by authors named "H B Kemp"
Scand J Pain
January 2024
Article Synopsis
- The study investigates how different pain syndromes influence levels of pain catastrophizing in patients.
- A total of 727 chronic pain patients were categorized into groups based on their pain syndrome: breast cancer survivors, fibromyalgia, complex regional pain syndrome, and HIV.
- Results revealed three distinct clusters of pain catastrophizing: low (mostly breast cancer patients), moderate (predominantly fibromyalgia patients), and high (mainly HIV and CRPS patients), with helplessness being a significant factor in the high catastrophizing group.
Article Synopsis
- The study explored genetic links to neuropathic pain by comparing individuals with the condition to those who had injuries but did not experience neuropathic pain.
- Key findings included significant associations with the KCNT2 gene and pain intensity, as well as other genes like LHX8 and TCF7L2 connected to neuropathic pain.
- The research also highlighted the influence of polygenic risk scores related to depression and inflammation on neuropathic pain, while discovering novel genetic variants tied to specific sensory profiles.
Article Synopsis
- * A consensus meeting in March 2024, attended by 28 experts and stakeholders, aimed to standardize research protocols for studying neuropathic pain using human peripheral tissues.
- * The meeting resulted in agreed-upon guidelines for phenotyping, laboratory protocols, statistical design, and data sharing to improve consistency in research and enhance understanding of neuropathic pain.
Article Synopsis
- Dual immune checkpoint blockade (ICB) using CTLA4 and PD-(L)1 inhibitors shows improved anti-tumor effectiveness and immune toxicity compared to PD-(L)1 inhibitors alone in advanced non-small-cell lung cancer (NSCLC) patients.
- Patients with mutations in STK11 and/or KEAP1 genes benefit more from the combination treatment compared to those receiving only PD-(L)1 inhibitors, as shown in the POSEIDON trial.
- The loss of KEAP1 serves as a strong predictor for the success of dual ICB, as it leads to a more favorable outcome by changing the tumor's immune environment to better engage CD4 and CD8 T cells for anti-tumor activity. *
